By Sherri Oslick --
About Court Report: Each week we will report briefly on recently filed biotech and pharma cases.
Senju Pharmaceutical Co. et al. v. Hi-Tech Pharmacal Co. Inc.
1:11-cv-00926; filed October 11, 2011 in the District Court of Delaware
• Plaintiffs: Senju Pharmaceutical Co.; Kyorin Pharmaceutical Co.; Allergan Inc.
• Defendant: Hi-Tech Pharmacal Co. Inc.
Infringement of U.S. Patent Nos. 6,333,045 ("Aqueous Liquid Pharmaceutical Composition Comprised of Gatifloxacin," issued December 25, 2001) and 5,880,283 ("8-Alkoxyquinolonecarboxylic Acid Hydrate With Excellent Stability and Process for Producing the Same," issued March 9, 1999), licensed to Allergan, following a Paragraph IV certification as part of Hi-Tech's filing of an ANDA to manufacture a generic version of Allergan's Zymaxid® (gatifloxacin ophthalmic solution, used to treat bacterial conjunctivitis). View the complaint here.
Pfizer Inc. et al.v. Watson Pharmaceuticals, Inc. et al.
2:11-cv-05860; filed October 7, 2011 in the District Court of New Jersey
• Plaintiffs: Pfizer Inc.; Alpha Pharmaceuticals LLC; King Pharmaceuticals, Inc.
• Defendants: Watson Pharmaceuticals, Inc.; Watson Laboratories Inc.; Watson Pharma, Inc.; Watson Laboratories, Inc. - Florida
Infringement of U.S. Patent Nos. 7,682,633 ("Pharmaceutical Composition," issued March 23, 2010), 7,682,634 ("Pharmaceutical Compositions," issued March 23, 2010), and 7,815,934 ("Sequestering Subunit and Related Compositions and Methods," issued October 19, 2010) following a Paragraph IV certification as part of Watson's filing of an ANDA to manufacture a generic version of Pfizer subsidiary King Pharmaceutical's EMBEDA® (morphine sulfate and naltrexone hydrochloride extended release capsules, used in the management of moderate to severe pain). View the complaint here.
Purdue Pharma L.P. et al.v. Ranbaxy Inc. et al.
1:11-cv-07104; filed October 7, 2011 in the Southern District of New York
• Plaintiffs: Purdue Pharma L.P.; The P.F. Laboratories, Inc.; Purdue Pharmaceuticals L.P.; Rhodes Technologies
• Defendants: Ranbaxy Inc.; Ranbaxy Pharmaceuticals Inc.; Ranbaxy Laboratories Ltd.
Infringement of U.S. Patent Nos. 7,674,799 ("Oxycodone Hydrochloride Having Less Than 25 PPM 14-Hydroxycodeinone," issued March 9, 2010), 7,674,800 (same title, issued March 9, 2010), and 7,683,072 (same title, issued March 23, 2010) following a Paragraph IV certification as part of Ranbaxy's filing of an ANDA to manufacture a generic version of Purdue Pharma's OxyContin® (controlled release oxycodone hydrochloride, used to treat pain). View the complaint here.
Novartis Pharmaceuticals Corp. et al.v. Alembic Pharmaceuticals Ltd. et al.
1:11-cv-07092; filed October 7, 2011 in the Southern District of New York
• Plaintiffs: Novartis Pharmaceuticals Corp.; Novartis AG; Novartis Pharma AG; Novartis International Pharmaceutical Ltd.
• Defendants: Alembic Pharmaceuticals Ltd.; Alembic Pharma Ltd.; Alembic Ltd.; Breckenridge Pharmaceutical, Inc.
Infringement of U.S. Patent No. 5,602,176 ("Phenyl Carbamate," issued February 11, 1997) following a Paragraph IV certification as part of Alembic's filing of an ANDA to manufacture a generic version of Novartis' Exelon® (rivastigmine tartrate, used to treat mild to moderate dementia of the Alzheimer's type, and mild to moderate dementia associated with Parkinson's disease). View the complaint here.
Comments